ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 96
  • Next Page »
Search Again »
  • Abstract Number: 0617 • ACR Convergence 2024

    Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation

    Clément triaille1, Neha Mohan Rao2, Gillian Rice3, Luis Seabra4, Sutherland Fraser5, Vincent Bondet6, Darragh duffy6, Andrew Gennery7, Benjamin Fournier8, Brigitte Bader-Meunier9, Christopher Troedson10, Gavin CLeary11, Helena Buso12, Jacqueline Dalby-Payne13, Ranade Prajakta14, Katrien Jansen15, Lien De Somer16, Marie-Louise Fremond17, Pimple Pallavi14, Melanie Wong18, Russel Dale10, Carine Wouters16, PIERRE QUARTIER19, Raju Khubchandani20 and Yanick Crow5, 1Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, 2NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, 3Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, 4Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France, Paris, France, 5MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, Edinburgh, United Kingdom, 6Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, 7: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom, 8Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, France, 9Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, 10T. Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, New South Wales, and University of Sydney, Australia, Sydney, Australia, 11: Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, Liverpool, United Kingdom, 12Department of Medicine - DIMED, University of Padova, Padova, Italy, Padova, Italy, 13Specialty of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Australia, Sydney, Australia, 14NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, India, 15Division of Pediatric Neurology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 16Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 17Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, United Kingdom, 18Department of Allergy and Immunology, Children's Hospital at Westmead, Westmead, Australia, Westmead, Australia, 19Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, 20SRCC Childrens Hospital, Mumbai, India

    Background/Purpose: To report on the largest cohort of C1Q deficient (C1QDef ) patients; to investigate the activation of Type 1 interferon pathway in the blood…
  • Abstract Number: 0907 • ACR Convergence 2024

    Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol

    Niamh Fanning1, Murray Cadzow2, Ruth Topless3, Chris Frampton4, Nicola Dalbeth5, Tony Merriman6 and Lisa Stamp4, 1University of Otago, Christchurch, New Zealand, 2University of Otago, Dunedin 9054, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand, 5University of Auckland, Auckland, New Zealand, 6University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
  • Abstract Number: 0920 • ACR Convergence 2024

    TGF-β Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation

    Paul Panipinto1 and Salahuddin Ahmed2, 1Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, 2Washington State University, Spokane, WA

    Background/Purpose: Monosodium urate (MSU)-induced inflammation is caused by the deposition of MSU crystals in the joints and periarticular tissues under conditions of hyperuricemia. These deposits…
  • Abstract Number: 0934 • ACR Convergence 2024

    Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies

    Isak Tengesdal1, Carlo Marchetti1, Tim L.Th. Jansen2, Marc Y. Donath3, Naomi Schlesinger4 and Charles Dinarello1, 1University of Colorado, Denver, CO, 21VieCuri Medisch Centrum, Venlo, Netherlands, 3University of Basel, Basel, Switzerland, 4University of Utah, Salt Lake City, UT

    Background/Purpose: NLRP3 is emerging as an attractive upstream target of the pathway to down-modulate rather than to completely neutralize IL-1ß levels in both acute and…
  • Abstract Number: 0983 • ACR Convergence 2024

    Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey

    Aleksander Lenert1, Mary E. Charlton1, Jacob J. Oleson1, Robyn Domsic2 and Polly Ferguson3, 1University of Iowa, Iowa City, IA, 2Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 3University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: General well-being, an individual’s subjective assessment of their life overall, may be impacted by arthritis. It is unclear if adults with arthritis have lower…
  • Abstract Number: 1073 • ACR Convergence 2024

    Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting

    Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA

    Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…
  • Abstract Number: 1080 • ACR Convergence 2024

    Electronic Consults to Rheumatology: A One-Year Analysis of Referral Outcomes and Trends in Access

    Jeanne Gosselin1, Brendan Thoms2, Bonita Libman3, Tessalyn Morrison3, George McLane2 and Teresa Fama4, 1University of Vermont Medical Center, Waterbury, VT, 2University of Vermont Medical Center, South Burlington, VT, 3University of Vermont Medical Center, Burlington, VT, 4Univ of Vermont Health Network-Central Vermont Medical Center, Jericho, VT

    Background/Purpose: Access to rheumatologic care is severely limited at our academic medical center with wait times of 9 months or longer for routine new patient…
  • Abstract Number: 1085 • ACR Convergence 2024

    Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment

    Ashish Kumar1, Ali Hariri1, Yunjung Lee2 and Minhyung Lee2, 1LG Chem Life Sciences USA, Boston, MA, 2LG Chem, Seoul, Republic of Korea

    Background/Purpose: Tigulixostat is a potent and highly selective non-purine based xanthine oxidase inhibitor (XOi) being investigated for the management of hyperuricemia in patients with gout.…
  • Abstract Number: 1090 • ACR Convergence 2024

    Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy

    Naomi Schlesinger1, Katie Obermeyer2, Lissa Padnick-Silver2, Brian LaMoreaux3 and Peter Lipsky4, 1University of Utah, Salt Lake City, UT, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen, Inc., Deerfield, IL, 4AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…
  • Abstract Number: 1094 • ACR Convergence 2024

    Longitudinal Analysis of Serum Urate in Prediabetic Phase

    Javier Marrugo1, Leah Santacroce1, Misti Paudel2, Sho Fukui3, Sara Tedeschi1 and Daniel Solomon4, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 3Brigham and Women's Hospital, Brookline, MA, 4Brigham and Women's Hospital, Newton, MA

    Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
  • Abstract Number: 1109 • ACR Convergence 2024

    Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women

    Laura Scagnellato1, Antonio Collesei2, Sonia farah3, Carlomaurizio Montecucco4, Francesca Oliviero5, Bernd raffeiner6, Marta favero5, Amelia Damasco5, doria Andrea5, Fausto Salaffi3 and Roberta Ramonda7, and SIR Study Group on Crystal Arthropaties, 1Rheumatology Unit, University of Padova, Padova, Italy, 2IRCCS Istituto Oncologico Veneto IOV, Padova, Italy, 3Polytechnic University of Marche, Jesi (AN), Italy, 4IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 5University of Padova, Padova, Italy, 6General Hospital of Bolzano, Bolzano, Italy, 7Rheumatology Unit, University of Padova, Italy, Padova, Italy

    Background/Purpose: Crystal arthropaties, including gout and calcium pyrophosphate deposition disease (CPPD), are prevalent and burdensome conditions. The ALLSTAR model allows the identification of reliable causal,…
  • Abstract Number: 1220 • ACR Convergence 2024

    Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution

    Seth Adler1, Osama Al Zoubi2 and Robert Katz3, 1Rheumatology Associates, Rush University Medical Center, Chicago, 2University of Illinois at Chicago, Chicago, IL, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: Recent estimates predict that up to 12 million adults in the United States suffer from Fibromyalgia Syndrome (FMS). That is compared to around 1.3…
  • Abstract Number: 1245 • ACR Convergence 2024

    Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative

    Stephanie Tancer1, Basmah Al Dulaijan2 and Puja Khanna3, 1University of Michigan Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, 2Michigan Medicine, Ann Arbor, MI, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain when left untreated. Allopurinol is…
  • Abstract Number: 1300 • ACR Convergence 2024

    Tackling Rheumatology Workforce Shortages with a Case-Based Primary Care Rheumatology Curriculum

    Diego Cabrera1, Betty Hsiao2 and Fotios Koumpouras1, 1Yale School of Medicine, New Haven, CT, 2Yale-New Haven Medical Center, New Haven, CT

    Background/Purpose: Rheumatology is facing an imminent workforce shortage adversely affecting patients’ access to care. Primary care physicians are key stakeholders in the early evaluation and…
  • Abstract Number: 1352 • ACR Convergence 2024

    The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems

    Gregory McDermott1, Xin Xiong2, Rachel Knevel3, Jing Cui4, Mary Jeffway4, Vidul Panickan5, Andrew Cagan4, Rahul Sangar6, Daniel Posner6, Lauren Costa6, Rachael Matty6, Elizabeth Karlson4, Yuk-Lam Ho6, Kelly Cho6, Rui Duan2, Tianxi Cai2 and Katherine Liao4, 1Brigham and Women's Hospital, Brookline, MA, 2Harvard T.H. Chan School of Public Health, Boston, MA, 3Leiden University Medical Center, Leiden, Netherlands, 4Brigham and Women's Hospital, Boston, MA, 5Harvard Medical School, Boston, MA, 6U.S. Department of Veterans Affairs, Boston, MA

    Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 96
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology